The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro

Summary

The direct thrombin inhibitor argatroban offers some significant advantages over unfractionated heparin (UFH) and is recommended as an alternative anticoagulant during percutaneous coronary interventions (PCI). The impact of argatroban on cardiac catheter thrombosis – a severe potential complication of PCI – has not been systematically studied yet. The aim of the present study was to test in vitro the hypothesis that argatroban is equivalent to the more established anticoagulants UFH and enoxaparin in preventing catheter thrombus formation. Blood pretreated with the anticoagulants of interest was continuously circulated through a guiding catheter by using a roller pump for a maximum experimental period of 60 minutes. In an alternate model, coagulation was mechanically induced by a magnetic stirrer. Coagulation parameters, overall thrombus weight and electron microscopic features (deposits of platelets and fibrin on the catheter surface) were quantified as endpoints. Argatroban (administered as bolus or continuous in-fusion), UFH (bolus), and enoxaparin (bolus) significantly reduced catheter thrombus formation compared to untreated controls. Here, neither overall thrombus weight nor platelet/fibrin deposition was different among the specific anticoagulants. Declining ACT (activated clotting time) levels – which were found in the argatroban bolus group – could be prevented by continuous infusion. In magnetic stirrer-induced coagulation, thrombus weight was lower following bolus treatment with UFH and enoxaparin compared to argatroban. These data suggest that the potential for argatroban in preventing catheter thrombosis is comparable to that of UFH and enoxaparin. However, the anticoagula-tory efficacy varied, depending on the model of coagulation activation, which demonstrates the necessity for specific testing.

Keywords

Anticoagulation - direct thrombin inhibitors - PCI

• References

• 1 Bassand JP, Hamm CW, Ardissino D. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660.
• 2 Anderson JL, Adams CD, Antman EM. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116: e148-e304.
• 3 Antman EM, Hand M, Armstrong PW. et al. 2007 Focused Update of the ACC/ AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008; 117: 296-329.
• 4 Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-256.
• 5 Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation 2005; 111: 2671-2683.
• 6 Lepor NE. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors. Rev Cardiovasc Med 2007; 08 (Suppl. 03) S9-17.
• 7 Lewis BE, Hursting MJ. Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther 2007; 05: 57-68.
• 8 Silber S, Albertsson P, Aviles FF. et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-847.
• 9 Smith SC Jr, Feldman TE, Hirshfeld JW Jr. et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47: e1-121.
• 10 Hursting MJ, Alford KL, Becker JC. et al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997; 23: 503-516.
• 11 Cruz-Gonzalez I, Sanchez-Ledesma M, Baron SJ. et al. Efficacy and safety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome. J Thromb Thrombolysis 2008; 25: 214-218.
• 12 Hirahara T, Kubo N, Ohmura N. et al. Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary intervention for acute myocardial infarction. J Cardiol 2004; 44: 47-52.
• 13 Jang IK, Lewis BE, Matthai WH Jr. et al. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study. J Thromb Thrombolysis 2004; 18: 31-37.
• 14 Agnelli G, Eriksson BI, Cohen AT. et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res 2009; 123: 488-497.
• 15 Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006; 129: 1167-1175.
• 16 Yusuf S, Mehta SR, Chrolavicius S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464-1476.
• 17 Yusuf S, Mehta SR, Chrolavicius S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. J Am Med Assoc 2006; 295: 1519-1530.
• 18 Schlitt A, Rupprecht HJ, Reindl I. et al. In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus. Coron Artery Dis 2008; 19: 279-284.
• 19 Maegdefessel L, Buerke M, Schubert S. et al. Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study. Thromb Haemost 2008; 100: 693-698.
• 20 Montalescot G, White HD, Gallo R. et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355: 1006-1017.
• 21 Iqbal O, Ahmad S, Lewis BE. et al. Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology. Clin Appl Thromb Hemost 2002; 08: 217-224.
• 22 Lincoff AM, Bittl JA, Harrington RA. et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. J Am Med Assoc 2003; 289: 853-863.
• 23 Stone GW, McLaurin BT, Cox DA. et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216.
• 24 Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99: 830-839.
• 25 Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-329.
• 26 Hirahara T, Kubo N, Ohmura N. et al. Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary intervention for acute myocardial infarction. J Cardiol 2004; 44: 47-52.
• 27 Grayburn PA, Willard JE, Brickner ME. et al. In vivo thrombus formation on a guidewire during intravascular ultrasound imaging: evidence for inadequate heparinization. Cathet Cardiovasc Diagn 1991; 23: 141-143.
• 28 Stabile E, Nammas W, Salemme L. et al. The CIAO (Coronary Interventions Anti-platelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J Am Coll Cardiol 2008; 52: 1293-1298.
• 29 Dana A, Nguyen CM, Cloutier S. et al. Macroscopic thrombus formation on angioplasty equipment following antithrombin therapy with enoxaparin. Catheter Cardiovasc Interv 2007; 70: 847-853.
• 30 Chia S, Van Cott EM, Raffel OC. et al. Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation. Thromb Haemost 2009; 101: 535-540.
• 31 Maegdefessel L, Linde T, Michel T. et al. Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves. Results of an in-vitro study. Thromb Haemost 2009; 101: 1163-1169.
• 32 Keuren JF, Wielders SJ, Willems GM. et al. Fibrinogen adsorption, platelet adhesion and thrombin generation at heparinized surfaces exposed to flowing blood. Thromb Haemost 2002; 87: 742-747.
• 33 Schmaier AH. The elusive physiologic role of Factor XII. J Clin Invest 2008; 118: 3006-3009.
• 34 Stief TW. Kallikrein activates prothrombin. Clin Appl Thromb Hemost 2008; 14: 97-98.
• 35 Kroll MH, Hellums JD, McIntire LV. et al. Platelets and shear stress. Blood 1996; 88: 1525-1541.
• 36 Miyazaki Y, Nomura S, Miyake T. et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood 1996; 88: 3456-3464.
• 37 Williams MS, Coller BS, Vaananen HJ. et al. Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab (c7E3 Fab; ReoPro). Circulation 1998; 98: 742-748.